Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04149990
Other study ID # Version 1.4
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 12, 2018
Est. completion date May 2023

Study information

Verified date October 2021
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study examines the effect of Entresto on central hemodynamic parameters during exercise in patients with diastolic dysfunction following acute myocardial infarction. Half of the patients will receive Entresto and the other half will receive placebo.


Description:

In patients with acute myocardial infraction (AMI) only 25-33% have entirely normal left ventricular (LV) systolic and diastolic function. Studies have show that echocardiographic signs of increased LV filling pressure (diastolic dysfunction) are associated with poor outcome after AMI. The optimal management of this group of patients is currently not known. LCZ696 is a novel combination drug consisting of two antihypertensives, sacubitril and valsartan. LCZ696 have demonstrated to reduce mortality in patients with systolic heart failure. In patients with heart failure with preserved ejection fraction a positive effect has been demonstrated on natriuretic peptides and left atrial remodelling when treated with LCZ696, further, experimental data suggest inhibition of cardiac fibrosis. Hypothesis: LCZ696 compared with placebo will improve central hemodynamics (reduce pulmonary capillary wedge pressure (PCWP)), and increase cardiac index (CI) during exercise in patients with diastolic dysfunction following AMI. A beneficial effect that is attributed to improved cardiac remodelling (attenuation of cardiac fibrosis). Primary objective To asses the effect of 6 months treatment with LCZ696 compared with placebo on ratio of PCWP/CI during exercise in patients with a recent AMI and Doppler echocardiographic signs of diastolic dysfunction and preserved systolic function.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 2023
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: 1. Documented ST segment elevation or non ST- myocardial infarction according to current guidelines 2. Complete revascularization 3. Age =50 years 4. LVEF =45% on echocardiography performed within 72 hours of the MI. 5. Diastolic dysfunction defined as: Ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus diastolic velocity (e') ratio > 8 and at least moderate LA dilatation (LA volume index>34 mL/m2). 6. Signed informed consent Exclusion Criteria: 1. Intolerance towards study medication 2. Permanent atrial fibrillation, 3. Known history of cardiomyopathy, 4. More than mild valvular heart disease, 5. Severe obstructive or restrictive pulmonary disease, 6. Inability to perform exercise testing, 7. Inadequate acoustic windows on echocardiography, 8. Ongoing treatment with an angiotensin converting enzyme inhibitor at randomization. 9. Class I indication for an angiotensin converting enzyme inhibitor 10. Symptomatic hypotension, a systolic blood pressure of less than 100 mm Hg at screening 11. An estimated glomerular filtration rate (eGFR) below 30 ml per minute per 1.73 m2 of body-surface area at any time, 12. A serum potassium level of more than 5.2 mmol per liter at screening, 13. A history of hereditary or idiopathic angioedema or unacceptable side effects during receipt of angiotensin converting enzyme inhibitor or angiotensin receptor blocker 14. Inability to provide informed consent 15. Concomitant use of drugs containing aliskiren in patients with diabetes mellitus. 16. Severe reduced liver function, biliary cirrhosis or cholestasis (Child-Pugh class C) 17. Pregnant or nursing(lactating) women(see section 8.2.1 for details) 18. Fertile women unless they are using a highly effective method of contraception(see section 8.2.2 for details)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Valsartan+ sacubitril
Treatment with Entresto(valsartan+sacubitril)
Placebo Oral Tablet
Matching placebo treatment

Locations

Country Name City State
Denmark Department of Cardiology, Rigshospitalet Copenhagen
Denmark Department of Cardiology, Odense Universityhospital Odense

Sponsors (4)

Lead Sponsor Collaborator
Jacob Moller Danish Heart Foundation, Odense University Hospital, Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Central hemodynamics The primary endpoint will be the ratio of mean PCWP at peak exercise divided by cardiac index at peak exercise. 26 weeks
Secondary cardiac MRI Amount of hyperenhancement on cardiac MRI using a semiquantitative assessment of late gadolinium hyperenhancement in a 17 segment model of the LV. 26 weeks
Secondary Biomarker ST2 concentration at rest. 26 weeks
Secondary Biomarker MR-proANP at rest. 26 weeks
Secondary Biomarker NT-proBNP at rest. 26 weeks
Secondary Echocardiographic Left atrial volume by echocardiography and left atrial emptying fraction by echocardiography at rest. 26 weeks
Secondary Echocardiographic Proportion of patients with moderate or severe diastolic dysfunction at rest.echocardiography at rest. 26 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Completed NCT04507529 - Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients N/A
Recruiting NCT06066970 - Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
Recruiting NCT03620266 - Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI N/A
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT03668587 - Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Recruiting NCT05371470 - Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation N/A
Recruiting NCT04562272 - Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT06007950 - Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health N/A
Withdrawn NCT05327855 - Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) Phase 2
Recruiting NCT02876952 - High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients N/A
Completed NCT02711631 - Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation N/A
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT02305602 - A Study of VentriGel in Post-MI Patients Phase 1
Completed NCT02552407 - Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis N/A